Friends! In this video, I'm going to do an analysis on Fiserv Stock and Intuitive surgical
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 27 Sept 2025, 20:18 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The current market analysis focuses on two stocks: FISV and ISRG. FISV is currently trading at $129.56, down 41.56% year-to-date and showing weakness. While its valuation metrics like P/E ratio and price to free cash flow are low (11.8x and 16.6x respectively), the significant debt load and declining EPS growth might be concerns. The stock has a bearish trend, but a potential bullish reversal is noted if it can break past $150. ISRG, trading at $441.12, has also seen a downturn, down 15.82% year-to-date. Despite a strong long-term growth trend and substantial revenue from recurring services, its recent EPS growth has slowed. The company's extensive installed base of Da Vinci robots and a strong recurring revenue model suggest resilience, but competition from Chinese manufacturers offering cheaper alternatives at 50% lower costs is a factor. A target of $470 is set for ISRG, with a failure bound at $438.50.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
